ProQR Therapeutics Appoints Dr. Peter Beal as Chief ADAR Scientist to Advance RNA Editing Platform
ProQR Therapeutics appoints Dr. Peter Beal as Chief ADAR Scientist to enhance RNA editing technology development.Quiver AI SummaryProQR Therapeutics has appointed Dr. Peter Beal, a prominent expert in...
Best Momentum Stocks to Buy for October 2nd
Here are three stocks with buy rank and strong momentum characteristics for investors to consider today, October 2:BRF S.A. BRFS: This meat processing company has a Zacks Rank #1 and witnessed the Zacks...
Why Shares of ProQR Therapeutics Dropped on Wednesday
The clinical-stage biotech released fourth-quarter and full-year earnings.
Lilly and ProQR to Expand RNA Editing Collaboration
/PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and ProQR Therapeutics N.V. (Nasdaq: PRQR), today announced the expansion of their licensing and...